RepliCel Life Sciences (TSXV:RP) 3-Year Revenue Growth Rate : -15.70% (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is RepliCel Life Sciences 3-Year Revenue Growth Rate?

RepliCel Life Sciences's Revenue per Share for the three months ended in Sep. 2023 was C$0.00.

During the past 12 months, RepliCel Life Sciences's average Revenue per Share Growth Rate was -40.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of RepliCel Life Sciences was 11.20% per year. The lowest was -15.70% per year. And the median was -2.25% per year.

Competitive Comparison of RepliCel Life Sciences's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, RepliCel Life Sciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RepliCel Life Sciences's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's 3-Year Revenue Growth Rate falls into.

RepliCel Life Sciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

RepliCel Life Sciences (TSXV:RP) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

RepliCel Life Sciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

RepliCel Life Sciences (TSXV:RP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (TSXV:RP) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

REPCF:USA P6P2:Germany

Address

570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1

Website

https://www.replicel.com

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.